PEARL
WE RESTORE MOBILITY
Restoring the function of joint surfaces using tissueengineering
Innovative Method
Proven results
Experienced Team
Patented therapy
No effective strategy for treatment young, active patients with cartilage leasions.
- The total degenerative patient population is increasing
- The age at which the first surgical treatment is performed is decreasing
- There are no effective treatments for small to medium articular cartilage lesions.
in 2030
The first THA (total hip arthroplasty) performed in younger patients will constitute 52%
The first TKA (total knee arthroplasty) 55%
Is a disease characterized by joint pain and dysfunction caused by the progressive and irreversible loss of joint cartilage.
At an advanced stage of the disease, it becomes necessary touseanendoprosthesis.Removal of the joint means its permanent destruction and the final loss of periarticular bone tissue.
In the case of disease progression and periimplant tissue degeneration,the next stage is an even more extensive excision of the tissues and theimplantation
of larger implant – which usually ends with a permanent disabilityafter revision surgeries.
130 million patients will be suffering
from osteoarthritis
40 million will be disabled
It is significant that the disease affects younger and younger patients, analyzing data so far
Value of the global endoprosthesis market:
2019 - USD 19.32 billion
2027 - USD 29.79 billion
5.6% CAGR
Global cartilage reconstruction market value:
2022 - USD 984,25 mln
2030 - USD 3 095,64 mln
15,4% CAGR
Worldwide, 9.6% of men and 18% of women over the age of 60 have symptoms of osteoarthritis.
80% of them suffer from limited movement and 25% areunable to perform basic life activities.
Disadvantages of traditional methods (endoprostheses)
The prosthesis does not rebuild into tissue. Its implantation destroys bone and cartilage irreversibly.
Progressive tissue lysis around the endoprosthesis.
Inability to fill and restore the tissue after loosening the implant.
In the case of peri-prosthetic fractures, it is necessary to replace with extensive damage to the bones and surrounding tissues.
Endoprosthesis loosening - revisions of endoprostheses lead to the loss of bone tissue and surrounding structures, which results in permanent disability.
Inability to reproduce the full range of motion. Inability to return to full fitness.
Hip prosthesis - risk of dislocation, Hip and knee prosthesis - complex periprosthetic bone fractures.
Age and health restrictions.
Significant risk of infection (not only perisurgical).
The need for revision surgery that appears along with the implantation of an endoprosthesis in younger age groups 45-55 (1- 3 per patient) - increased risk of complications.
Disadvantages of available biological methods
Lack of technology to restore full-thick and stable hyaline cartilage.
Limited effectiveness compared to traditional methods (endoprothesis).
Possibility to treat small cartilage defects.
Unknown effectiveness in people over 55 years of age.
High cost of therapy.
In the United States, only 0.4% of all surgically treated patients undergo regenerative treatment , but this group is gradually growing.
First Round - Completed
- Objectives – optimizationand validation of the method.
- Acquired capital – EUR 230 thousand.
- Duration of work – 8 quarters.
Second Round - Present
- Objectives – to conduct therapeutic medical experiments using the PEARL hospital exemption product PEARL-HE-ATMP (PEARL-hospital exemption advanced therapy medicinal product).
- Capital demand – EUR 230 thousand.
- Duration of work – 4 quarters.
Third Round
- Objectives – clinical tial and ATMP registration
- Capital demand EUR 3.8 million
- Duration of work – 14 quarters
meet Our Experienced team
Marek Putko
MBA - University of Gdansk, Universiteit Antwerpen RUCA, Copenhagen Business School, Fachhochschule Fur Technik und Wirtschaft in Berlin.
A manager with 30 years experience in sales and marketing, very good knowledge pharmaceutical market, practical experience in leading human resources, creating development strategy and sales of products, implementing marketing message.
For 30 years associated with the pharmaceutical and medical industry.
He participated in the creating and implementation of many innovative projects and products on the market.
Experience gained in many large international corporation and Polish local producers.
Wojciech Armuła
Graduate of the Kraków University of Economics.
Completed post-graduate studies in Accounting and Finance for the Advanced offered by the Kraków School of Business, which is a part of the Kraków University of Economics.
External expert for the Ministry of Energy (since 2016) and the Institute of Oil and Gas (since 2009) with respect to financial aspects of energy projects. Between 2009 and 2015, he was an expert of the Małopolska Center for Entrepreneurship (an assessor in terms of investment operations of enterprises).
Coach of the European Commission (EASME, the Horizon 2020 SME Instrument), providing financial consulting and coaching to SMEs.
Took active part in a number of IPOs and SPOs on the Warsaw Stock Exchange including NewConnect.
Focusing in corporate finance, mainly valuations of companies, business plans, feasibility studies.
Dr. Eng. Sławomir Jaros, Executive MBA
Executive MBA completed at the University of Lodz in cooperation with the University of Maryland.
An expert in managing projects related to the development of innovative therapies, including the most modern drug classes in the world.
Relating projects from the Start up phase to the WIG.
Experience in building companies, managing large units, including companies listed on the Warsaw Stock Exchange.
Building the Company on the WSE from New Connect to WIG40 within eight years.
Winner of awards and distinctions, including the Young Wolf of the Stock Exchange 2015.
Dr Grzegorz Sobieraj
Medical University of Lodz.
Orthopedics and traumatology specialist.
Member of the ESSKA , ICRS ,ESSSE , Polish Arthroscopic Society, Polish Orthopedic Society.
A pioneer in the field of innovative joint operating procedures.
Manager of the PCZ Orthopedic
Department in Brzeziny.
Medical Director of the Medical Hospital of the St. John of God Hospital in Łódź.
Head pshysician of the orthopedic ward in the Ortho Sport Clinic Private Hospital in Poland.
Iwona Makowska
For 17 years works in the clinical trials industry.
Experience in leading multiple global projects in Pharmacovigilance Department.
Experience in monitoring visits from start-up to close-out as Senior Clinical Research Associate.
Experience in managing clinical projects.
Experience in developing study specific documents.
Holds the European Medicines Agency certificates for EudraVigilance – electronic reporting of ICSRs and extended EudraVigilance Medicinal Product Dictionary (xEVMPD).
Experience in global submission to Regulatory Agencies and Ethics Committees.
Agnieszka Stochmal
Manager with over 15 years of experience in the capital market.
Co-founder of three capital funds with a total capitalization exceeding 50 million PLN.
Responsible for the entire investment and divestment process, portfolio supervision, and fund finances.
Her extensive experience also includes project management and the financial and substantive monitoring of projects.
Advisory Board
Prof. Ph.D. Justyna Drukała
Manager of the Tissue and Cell Bank and the ATMP Plant (responsible person under the Act of July 1, 2005 on the collection, storage and transplantation of cells, tissues and organs, qualified person under the Act of September 6, 2001 - Pharmaceutical Law).
Pioneer in the field of tissue engineering in Poland, specializes in the cultivation of skin cells - advanced therapy medicinal products for use in the treatment of severe burns (National Transplantation Program).
Conducts research on the regenerative potential of skin cells and cartilage cells.
Author of over 70 experimental and review publications.
Member of the National Transplantation Council (Development Strategy Team) and the Expert Committee of the Polish Burn Treatment Society
Grzegorz Stefański
A graduate of GUMED, SGH, UG.
For 25 years associated with the pharmaceutical and biotechnology industry.
Managing biotechnology companies, including those listed on the Warsaw Stock Exchange.
He developed and introduced innovative medical solutions to the market.
Creator of several patents.
Co-founder of the following companies: Mabion, Biophage, Tridens, Urteste, Human Biome Institute.
Co-founder of the Aligo Alfa investment fund.
Julita Balcerek
PhD student at the Medical University of Lodz.
Experience in managing projects related to the development of innovative therapies (from their direct implementation at the stage of research and development in the field of molecular biology and protein biochemistry to supervision of the process of creating and submitting registration documentation at EMA).
Experience in building and managing a team of the Research and Development Department.
Experience in managing teams implementing parts of a joint project - development of a biotechnological drug (manufacturing, quality control, research and development, clinical trials, quality assurance and regulation).
Creation and management of quality systems (GMP, GLP, GCP).
Starodworska 1
80-137 Gdansk, Poland
arthec@arthec.eu
WRITE US
A MESSAGE
ARTHEC Spółka Akcyjna
ul. Starodworska 1, 80-137 Gdańsk
NIP 583 336 71 06
KRS 0001103084
Kapitał zakładowy: 100.000 PLN
